Meda Acquires Exclusive Rights To New Treatment Of Actinic Keratosis
Links shared publicly online about this topic.
- 1,172total visits
Meda Acquires Exclusive Rights To New Treatment Of Actinic Keratosis
Meda has acquired exclusive European rights to a new formulation of imiquimod from Graceway Pharmaceuticals. The new formulation is 3,75% imiquimod topical cream indicated for the treatment of act
View full resource at medicalnewstoday.com
Tags: Dermatology, Dairy, Pharma
Most Recently Shared on May 13, 2010 at 1:08 pm By:
Meda Acquires Exclusive Rights To New Treatment Of Actinic Keratosis http://mnt.to/3CxP #dermatology
Advertisement
